Adicet Bio Advances Prula-Cel Toward SLE Data Readout
REDWOOD CITY, Calif., September 1, 2026 Adicet Bio announced completion of the last patient visit for the planned Phase...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
REDWOOD CITY, Calif., September 1, 2026 Adicet Bio announced completion of the last patient visit for the planned Phase...
FOSTER CITY, Calif. – August 27, 2026 Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA)...
REDWOOD CITY, Calif. – August 27, 2026 Adicet Bio, Inc. announced that the U.S. Food and Drug Administration (FDA)...
Melbourne, Australia & Indianapolis, Indiana, USA | July 22, 2026 Telix Pharmaceuticals announced the peer-reviewed publication of results from...
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 14, 2026 ORIC Pharmaceuticals announced the initiation of the global Himalayas-1...
Melbourne, Australia, and Indianapolis, Indiana, United States, July 2, 2026 Telix announced a significant regulatory milestone after a successful...
MELBOURNE, Australia & INDIANAPOLIS, U.S., June 2, 2026 Telix Pharmaceuticals announced positive Part 1 data from its global Phase...
CAMBRIDGE, Mass., June 2, 2026 Convergent Therapeutics announced positive interim Phase 2 data from its CONVERGE-01 study evaluating CONV01-α...
BOSTON, June 1, 2026 Foundation Medicine announced that the U.S. Food and Drug Administration (FDA) has approved both FoundationOne®...
SILICON VALLEY, Calif. & BEIJING, June 1, 2026 Haisco Pharmaceutical Group Co., Ltd. has announced a landmark licensing and...
